Mar 27,2023

Dario Selected as Digital Therapeutics Partner by a Top-Ten Digitally Enabled Pharmacy Benefits Manager

DarioHealth announced a new contract with a leading nationwide Pharmacy Benefits Manager operating in 50 states to provide Dario's digital therapeutics, starting with the diabetes solution, to employer clients beginning in the second quarter of 2023. Through the new contract, the PBM will replace an existing digital diabetes solution with Dario's cardio metabolic digital therapeutic. Members who are currently users of the PBM's digital diabetes offering will be transitioned to Dario upon launch, which is expected to generate revenue in the second quarter and grow significantly through the rest of 2023. The agreement is the first contract to originate through Dario's previously announced strategic partnership with Sanofi U.S., representing a milestone achievement one year into the agreement.

COLLABORATION PARTNERSHIP

#institution

#dtx

View Analyst & Ambassador Comments
Go to original news
Mar 27,2023

New Study from Teladoc Health Further Validates the Effectiveness of a Single, Integrated Care Experience

Teladoc Health, the global leader in whole-person virtual care, today released new findings from a peer-reviewed study showing individual improvements in A1c, systolic blood pressure and weight, when enrolled in multiple chronic condition management programs over time. Individuals participating only in a diabetes program with a self-reported A1c greater than 7% who then engaged with hypertension, weight management and mental health programs saw an additional reduction in A1c (0.44%). Individuals starting on the weight management program with a BMI greater or equal to 30 who then engaged in three programs, saw an additional 1.0% reduction in body weight.

CLINICAL STUDY

#virtual care

View Analyst & Ambassador Comments
Go to original news
Mar 24,2023

ViCentra now offers Kaleido insulin pump in the Netherlands

ViCentra recently announced that it made its Kaleido insulin pump system available for users in the Netherlands. Kaleido features pulse technology that provides continuous micro-dosing of insulin. Each user can choose to wear the discreet pump directly on the body or in its pocket when using its longer tubing option. Later this year, ViCentra plans to make Kaleido available in combination with the DBLG1 system from Diabeloop connected to Dexcom 6 CGM.

PRODUCT

#insulin pump

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Mar 24,2023

Medtronic prices $2 billion of senior notes

Medtronic announced that its Medtronic Global Holdings S.C.A subsidiary priced an offering of senior notes worth $2 billion. The financial move comes at the same time that the world’s largest medical device company engages in significant expense reductions. The idea is to boost the company’s resilience against the present macroeconomic headwinds. The wholly-owned subsidiary — Medtronic Luxco — priced the offering of two different groups of senior notes. The first, with a principal amount of $1 million, includes 4.25% senior notes due in 2028. Medtronic Luxco’s second group of notes features $1 million of 4.5% senior notes due 2023.

FUNDING POST-IPO DEBT
View Analyst & Ambassador Comments
Go to original news
Mar 23,2023

Welldoc Earns 2023 BIG Artificial Intelligence Excellence Award

Welldoc has been named an Artificial Intelligence Excellence Award winner for its chronic care platform that integrates personalized, actionable insights into the daily lives of individuals living with chronic conditions and comorbidities. The scalable platform provides AI-driven digital coaching focused on total health across diabetes, pre-diabetes, hypertension, heart failure, weight management and includes mental well-being guidance, which is an essential aspect of holistic chronic care.

PRODUCT

#coaching

View Analyst & Ambassador Comments
Go to original news
Mar 22,2023

Dario Announces Strategic Partnership with Amwell to Expand Access to its Cardiometabolic Digital Therapeutic Solution

DarioHealth Corp announced today a strategic partnership with Amwell to deliver its cardiometabolic solution to Amwell customers. Dario's solution will be available through Amwell beginning in the second half of 2023. The agreement is part of Dario's strategy to partner with market leading strategic partners to accelerate adoption of Dario's solutions by making the Dario solution available to existing Amwell customers. Members living with cardiometabolic health concerns such as diabetes, high blood pressure and weight management challenges will have access to Dario's proven and highly personalized digital solution to help better manage their condition and improve outcomes between visits with clinicians practicing on the Amwell platform. Members can access Dario's solutions directly through Amwell's digital care delivery enablement platform to support ease of engagement.

COLLABORATION PARTNERSHIP

#institution

#dtx

#telehealth

View Analyst & Ambassador Comments
Go to original news
Mar 22,2023

Know Labs establishes scientific advisory board to advance non-invasive glucose monitoring

Know Labs announced today that it established a scientific advisory board to accelerate development for its glucose monitoring devices. Seattle-based Know Labs expects the members to advise on algorithm refinement, device development, clinical trial design and research publication strategy. They’ll work alongside the company’s current medical and regulatory advisory board members. Know Labs develops its proprietary Bio-RFID technology. It uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The company said the new advisory board “will be pivotal” in helping the company accelerate development and delivery for Bio-RFID.

PRODUCT

#bgm

View Analyst & Ambassador Comments
Go to original news
Mar 21,2023

Manitoba Becomes a Provincial Trailblazer in Providing Simplified Access to Advanced Glucose Monitors

Dexcom, Inc. announced that its Dexcom G6 CGM System will be available to people of all ages with type 1 and type 2 diabetes in Manitoba who meet eligibility criteria. As of this announcement, Manitoba is currently the only province in Canada that does not require an application for preapproval of coverage which means improved access for patients and reduced workload for prescribers.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 21,2023

Nemaura Medical to Participate in Fireside Chat Hosted by EF Hutton

Discussion topics will likely include Nemaura’s unique glucose monitoring device and its complementary digital health solutions, the Company’s commercial strategy and channel partnerships, early Miboko patient data from its UK pilot program, and the regulatory progress with the FDA.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Mar 21,2023

Diabeloop announces collaboration with Novo Nordisk to pursue its interoperability strategy with connected insulin pens

The agreement covers integrating DBL-4pen, Diabeloop’s self-learning algorithm for MDI therapy, with Novo Nordisk’s connected and reusable insulin pens, NovoPen® 6 and NovoPen Echo® Plus. DBL-4pen is a self-learning basal and bolus recommendation app for people with Type 1 and Type 2 diabetes who take multiple daily insulin injections (MDI). NovoPen® 6 and NovoPen Echo® Plus are connected pens with a dose memory function that keeps a history of the last 800 insulin injections and shows on a built-in digital display the number of units administered during the last injection, as well as the time since that injection. Diabeloop will then initiate a dedicated clinical study, to assess the efficacy and the clinical benefits of the combined solution connecting DBL-4pen with NovoPen® 6 and NovoPen Echo® Plus connected pens. The insulin pen data will be transmitted to the DBL-4pen self-learning algorithm to recommend the dose of insulin to be injected in real-time from meail time and exercise data input.

COLLABORATION PARTNERSHIP

#r&d

#insulin pen

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES